AbbVie Inc. remains optimistic, despite some outside safety concerns, that its late-stage immunology drug candidates can increase its market share in autoimmune disease at a time when its top-selling powerhouse Humira (adalimumab) is facing increased competition from both biosimilars and new branded agents.
AbbVie talked up a number of pipeline milestones expected in the second half of 2017 during its July 28 second...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
